title: An open study with acamprosate in Belgium and Luxemburg: results on sociodemographics, supportive treatment and outcome.
abstract: This open study on 614 alcohol-dependent patients from 51 centres in Belgium over 24 weeks collected data on the sociodemographic, medical and drug safety profiles and the type of psychosocial support most commonly associated with acamprosate. Psychiatric problems (34%) and gastro-intestinal ulcers (15%) were the most frequent other medical diagnoses. As supportive treatment, 48% of patients received individual psychotherapy, 25% group therapy, 16% relapse prevention and coping skills, 9% brief intervention and 2% family therapy. Fifteen (29%) centres used only 1 form of supportive treatment, 14 (27%) used 2 forms of support, 16 (31%) used 3 forms, 4 (8%) used 4 and only 2 centres (4%) used all 5 supportive treatment options. Three hundred and fifty-nine patients dropped out of the study. At any moment during the treatment period, up to 11% relapsed, 9% had binge drinking and 9% had drinking lapses. The quantity of alcohol consumption during relapse, lapse or binge drinking showed a considerable drop in the mean number of drinks per day, from 19.53 before treatment to 4.23-7.83 drinks for lapse drinking, 9.27-14.62 drinks for binge drinking and 4.96-10.29 drinks per day for relapse. All 8 dimensions of the SF36 quality of life questionnaire improved over the treatment period. Acamprosate was well tolerated by all patients.
authors.affiliation: Kliniek Broeders Alexianen, Tienen, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Ansoms
authors.forename: F
authors.initials: F
authors.lastname: Deckers
authors.forename: P
authors.initials: P
authors.lastname: Lehert
authors.forename: I
authors.initials: I
authors.lastname: Pelc
authors.forename: A
authors.initials: A
authors.lastname: Potgieter
mesh_terms: D000077443:Acamprosate; D000328:Adult; D000427:Alcohol Deterrents / Q000009:adverse effects / Q000627:therapeutic use*; D000437:Alcoholism / Q000534:rehabilitation*; D001530:Belgium; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008189:Luxembourg; D008297:Male; D008875:Middle Aged; D011613:Psychotherapy; D013654:Taurine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000427:Alcohol Deterrents; D013654:Taurine; D000077443:Acamprosate